Compare T-Mobile Us Inc (TMUS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs 10X Genomics Inc — how do they compare? T-Mobile Us Inc trades at $177.55 (market cap $194.89B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: T-Mobile Us Inc is far larger — about 22.8× 10X Genomics Inc's market cap, and T-Mobile Us Inc pays a 2.25% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TMUS | TXG | |
|---|---|---|
Market Cap | $194.89B | $8.55B |
Sector | Media | Health |
52-Week High | $241.67 | $67.29 |
52-Week Low | $167.65 | $11.34 |
Enterprise Value | $311.51B | $8.08B |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement (+0.09%) amid a bearish technical signal. The company demonstrates strong fundamentals with $88.3B revenue (2025) and consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80% buy ratings and a $233.20 consensus target, though technical indicators show near-term resistance at $183. Recent developments include CFO transition planning and institutional accumulation by California State Teachers Retirement System.
TMUS presents a compelling growth story with solid profitability metrics and analyst support, though technical weakness and competitive pressures warrant caution. The stock's 28% upside to consensus target offers potential, but investors must weigh strong cash flow generation against rising debt levels and sector-wide pricing pressures evident in recent broadband repricing trends.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
